Program performance
What students demonstrated through program assessments across Years 1–3 and academic years.
What does the available evidence tell us about how well students are achieving the intended learning outcomes of this stream?
This workspace brings together what students demonstrate in program assessments, external licensure performance, and graduating-student self-report. These perspectives remain distinct so reviewers can understand what each contributes before considering the overall achievement picture.
What evidence am I reviewing?
What students demonstrated through program assessments across Years 1–3 and academic years.
PEBC MCQ and OSCE results provide an external perspective on achievement. The two components remain separate because they use different measures.
AFPC and CCAPP self-report evidence shows how graduating students describe preparedness and where they report developing knowledge and skills.
What do program assessments show about student performance in this stream?
Third-year course averages dropped notably from two academic years ago to the previous academic year and remained slightly lower in the selected academic year.
In the selected academic year first-year results rose relative to the previous academic year and exceeded two academic years ago, with a larger share of students in higher score ranges.
| PHARM 201 | Year 1 | 2025-2026 | 137 | 82.9% | 85.2% | 8.3% |
| PHARM 201 | Year 1 | 2024-2025 | 135 | 83.2% | 84.5% | 9.1% |
| PHARM 201 | Year 1 | 2023-2024 | 136 | 94.3% | 94.4% | 2.4% |
| PHARM 202 | Year 1 | 2025-2026 | 139 | 80.3% | 80.2% | 6.3% |
| PHARM 202 | Year 1 | 2024-2025 | 134 | 69.4% | 69.6% | 10.1% |
| PHARM 202 | Year 1 | 2023-2024 | 136 | 66.7% | 67.1% | 11.0% |
| PHARM 203 | Year 1 | 2025-2026 | 139 | 80.8% | 82.1% | 11.0% |
| PHARM 203 | Year 1 | 2024-2025 | 135 | 77.5% | 76.8% | 11.1% |
| PHARM 203 | Year 1 | 2023-2024 | 136 | 76.9% | 78.4% | 10.7% |
| PHARM 204 | Year 1 | 2025-2026 | 139 | 85.1% | 86.1% | 8.0% |
| PHARM 204 | Year 1 | 2024-2025 | 135 | 85.2% | 87.2% | 7.8% |
| PHARM 204 | Year 1 | 2023-2024 | 136 | 81.2% | 82.7% | 8.8% |
| PHARM 233 | Year 1 | 2025-2026 | 139 | 81.7% | 83.0% | 9.6% |
| PHARM 233 | Year 1 | 2024-2025 | 134 | 82.7% | 84.2% | 8.9% |
| PHARM 233 | Year 1 | 2023-2024 | 136 | 79.9% | 80.4% | 9.3% |
| PHARM 302 | Year 2 | 2025-2026 | 134 | 70.9% | 70.6% | 8.3% |
| PHARM 302 | Year 2 | 2024-2025 | 133 | 69.6% | 70.0% | 7.6% |
| PHARM 302 | Year 2 | 2023-2024 | 138 | 67.7% | 67.2% | 7.2% |
| PHARM 303 | Year 2 | 2025-2026 | 132 | 75.6% | 75.5% | 8.1% |
| PHARM 303 | Year 2 | 2024-2025 | 133 | 72.2% | 72.1% | 8.5% |
| PHARM 303 | Year 2 | 2023-2024 | 140 | 70.4% | 70.3% | 9.8% |
| PHARM 310 | Year 2 | 2025-2026 | 134 | 89.0% | 90.0% | 5.9% |
| PHARM 310 | Year 2 | 2024-2025 | 133 | 85.7% | 87.0% | 7.0% |
| PHARM 310 | Year 2 | 2023-2024 | 139 | 87.1% | 88.0% | 6.0% |
| PHARM 401 | Year 3 | 2025-2026 | 130 | 74.3% | 73.9% | 7.0% |
| PHARM 401 | Year 3 | 2024-2025 | 135 | 72.8% | 72.7% | 8.3% |
| PHARM 401 | Year 3 | 2023-2024 | 126 | 73.1% | 73.0% | 7.9% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
Course-level results dropped substantially from three academic years ago to two academic years ago and have edged down in the years since, leaving current results lower than earlier.
In the selected academic year, Years one and two concentrate more students in the mid-to-higher score bands, while Year three shows a larger share of students in the lower score bands.
| PHARM 201 | Year 1 | 2025-2026 | 137 | 82.9% | 85.2% | 8.3% |
| PHARM 201 | Year 1 | 2024-2025 | 135 | 83.2% | 84.5% | 9.1% |
| PHARM 201 | Year 1 | 2023-2024 | 136 | 94.3% | 94.4% | 2.4% |
| PHARM 202 | Year 1 | 2025-2026 | 139 | 80.3% | 80.2% | 6.3% |
| PHARM 202 | Year 1 | 2024-2025 | 134 | 69.4% | 69.6% | 10.1% |
| PHARM 202 | Year 1 | 2023-2024 | 136 | 66.7% | 67.1% | 11.0% |
| PHARM 203 | Year 1 | 2025-2026 | 139 | 80.8% | 82.1% | 11.0% |
| PHARM 203 | Year 1 | 2024-2025 | 135 | 77.5% | 76.8% | 11.1% |
| PHARM 203 | Year 1 | 2023-2024 | 136 | 76.9% | 78.4% | 10.7% |
| PHARM 204 | Year 1 | 2025-2026 | 139 | 85.1% | 86.1% | 8.0% |
| PHARM 204 | Year 1 | 2024-2025 | 135 | 85.2% | 87.2% | 7.8% |
| PHARM 204 | Year 1 | 2023-2024 | 136 | 81.2% | 82.7% | 8.8% |
| PHARM 233 | Year 1 | 2025-2026 | 139 | 81.7% | 83.0% | 9.6% |
| PHARM 233 | Year 1 | 2024-2025 | 134 | 82.7% | 84.2% | 8.9% |
| PHARM 233 | Year 1 | 2023-2024 | 136 | 79.9% | 80.4% | 9.3% |
| PHARM 302 | Year 2 | 2025-2026 | 134 | 70.9% | 70.6% | 8.3% |
| PHARM 302 | Year 2 | 2024-2025 | 133 | 69.6% | 70.0% | 7.6% |
| PHARM 302 | Year 2 | 2023-2024 | 138 | 67.7% | 67.2% | 7.2% |
| PHARM 303 | Year 2 | 2025-2026 | 132 | 75.6% | 75.5% | 8.1% |
| PHARM 303 | Year 2 | 2024-2025 | 133 | 72.2% | 72.1% | 8.5% |
| PHARM 303 | Year 2 | 2023-2024 | 140 | 70.4% | 70.3% | 9.8% |
| PHARM 310 | Year 2 | 2025-2026 | 134 | 89.0% | 90.0% | 5.9% |
| PHARM 310 | Year 2 | 2024-2025 | 133 | 85.7% | 87.0% | 7.0% |
| PHARM 310 | Year 2 | 2023-2024 | 139 | 87.1% | 88.0% | 6.0% |
| PHARM 401 | Year 3 | 2025-2026 | 130 | 74.3% | 73.9% | 7.0% |
| PHARM 401 | Year 3 | 2024-2025 | 135 | 72.8% | 72.7% | 8.3% |
| PHARM 401 | Year 3 | 2023-2024 | 126 | 73.1% | 73.0% | 7.9% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
Scores fell after two academic years ago into the next year and remained lower for several years before a modest rise in the selected academic year.
In the selected academic year Year one and Year two moved higher compared with the previous academic year, with Year two showing no students in the lowest score band and Year three only modestly higher.
| PHARM 201 | Year 1 | 2025-2026 | 137 | 82.9% | 85.2% | 8.3% |
| PHARM 201 | Year 1 | 2024-2025 | 135 | 83.2% | 84.5% | 9.1% |
| PHARM 201 | Year 1 | 2023-2024 | 136 | 94.3% | 94.4% | 2.4% |
| PHARM 202 | Year 1 | 2025-2026 | 139 | 80.3% | 80.2% | 6.3% |
| PHARM 202 | Year 1 | 2024-2025 | 134 | 69.4% | 69.6% | 10.1% |
| PHARM 202 | Year 1 | 2023-2024 | 136 | 66.7% | 67.1% | 11.0% |
| PHARM 203 | Year 1 | 2025-2026 | 139 | 80.8% | 82.1% | 11.0% |
| PHARM 203 | Year 1 | 2024-2025 | 135 | 77.5% | 76.8% | 11.1% |
| PHARM 203 | Year 1 | 2023-2024 | 136 | 76.9% | 78.4% | 10.7% |
| PHARM 204 | Year 1 | 2025-2026 | 139 | 85.1% | 86.1% | 8.0% |
| PHARM 204 | Year 1 | 2024-2025 | 135 | 85.2% | 87.2% | 7.8% |
| PHARM 204 | Year 1 | 2023-2024 | 136 | 81.2% | 82.7% | 8.8% |
| PHARM 233 | Year 1 | 2025-2026 | 139 | 81.7% | 83.0% | 9.6% |
| PHARM 233 | Year 1 | 2024-2025 | 134 | 82.7% | 84.2% | 8.9% |
| PHARM 233 | Year 1 | 2023-2024 | 136 | 79.9% | 80.4% | 9.3% |
| PHARM 302 | Year 2 | 2025-2026 | 134 | 70.9% | 70.6% | 8.3% |
| PHARM 302 | Year 2 | 2024-2025 | 133 | 69.6% | 70.0% | 7.6% |
| PHARM 302 | Year 2 | 2023-2024 | 138 | 67.7% | 67.2% | 7.2% |
| PHARM 303 | Year 2 | 2025-2026 | 132 | 75.6% | 75.5% | 8.1% |
| PHARM 303 | Year 2 | 2024-2025 | 133 | 72.2% | 72.1% | 8.5% |
| PHARM 303 | Year 2 | 2023-2024 | 140 | 70.4% | 70.3% | 9.8% |
| PHARM 310 | Year 2 | 2025-2026 | 134 | 89.0% | 90.0% | 5.9% |
| PHARM 310 | Year 2 | 2024-2025 | 133 | 85.7% | 87.0% | 7.0% |
| PHARM 310 | Year 2 | 2023-2024 | 139 | 87.1% | 88.0% | 6.0% |
| PHARM 401 | Year 3 | 2025-2026 | 130 | 74.3% | 73.9% | 7.0% |
| PHARM 401 | Year 3 | 2024-2025 | 135 | 72.8% | 72.7% | 8.3% |
| PHARM 401 | Year 3 | 2023-2024 | 126 | 73.1% | 73.0% | 7.9% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
How well are our assessments functioning as measures of student performance?
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Year one exams show more consistently higher reliability, Year two exams display the greatest variability between sittings, and Year three exams are lower and more tightly clustered.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Discrimination (whether higher-performing students on the rest were more likely to answer correctly) identifies items that give little or negative separation and so should be prioritized for review.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Year one exams tend to show higher reliability, whereas Year two and Year three exams have lower medians with Year three clustering toward the lower end of the observed range.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Because difficulty shows how often students answer a question correctly and discrimination shows whether higher-scoring students also answer correctly, negative-discrimination items that move opposite the exam are the most actionable review signal.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Year one exams generally show higher and more consistent reliability while Year three exams are lower and tighter, suggesting multiple related assessments could increase overall score stability.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Whether higher-scoring students on the rest of the exam were more likely to answer correctly gives the clearest cue for which items need content, key, or alignment review, including negative movers.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
How prepared do graduating students say they are, and where do they believe knowledge and skills were developed?
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| pharmaceutics | |
| pharmaceutical biotechnology | |
| biopharmaceutics | |
| biochemistry | |
| molecular and cell biology | |
| anatomy | |
| pharmacokinetics | |
| medicinal chemistry |
| anatomy | 2026 | 4 | 36.9 |
| biochemistry | 2026 | 4 | 24.7 |
| immunology | 2026 | 5 | 67.9 |
| microbiology | 2026 | 5 | 52.9 |
| molecular and cell biology | 2026 | 4 | 34.1 |
| pathophysiology | 2026 | 5 | 79.8 |
| physiology | 2026 | 5 | 70.6 |
| biopharmaceutics | 2026 | 4 | 21 |
| biopharmaceutics | 2025 | 4 | 21 |
| biopharmaceutics | 2024 | 4 | 22 |
| medicinal chemistry | 2026 | 5 | 53 |
| medicinal chemistry | 2025 | 4 | 40.2 |
| medicinal chemistry | 2024 | 4 | 46.1 |
| pharmaceutical biotechnology | 2026 | 4 | 11.4 |
| pharmaceutical biotechnology | 2025 | 4 | 20 |
| pharmaceutical biotechnology | 2024 | 4 | 16.5 |
| pharmaceutics | 2026 | 4 | 25.3 |
| pharmaceutics | 2025 | 3 | 22 |
| pharmaceutics | 2024 | 3 | 19.8 |
| pharmacogenomics | 2025 | 4 | 33.8 |
| pharmacogenomics | 2024 | 4 | 36.3 |
| pharmacokinetics | 2026 | 4 | 33.7 |
| pharmacokinetics | 2025 | 4 | 30.9 |
| pharmacokinetics | 2024 | 3 | 20.8 |
| pharmacology | 2026 | 5 | 81.9 |
| pharmacology | 2025 | 5 | 77.8 |
| pharmacology | 2024 | 5 | 71.6 |
| toxicology | 2026 | 5 | 61.4 |
| toxicology | 2025 | 4 | 45.1 |
| toxicology | 2024 | 4 | 46.1 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| pharmaceutics | |
| pharmaceutical biotechnology | |
| biopharmaceutics | |
| biochemistry | |
| molecular and cell biology | |
| anatomy | |
| pharmacokinetics | |
| medicinal chemistry |
| anatomy | 2026 | 4 | 36.9 |
| biochemistry | 2026 | 4 | 24.7 |
| immunology | 2026 | 5 | 67.9 |
| microbiology | 2026 | 5 | 52.9 |
| molecular and cell biology | 2026 | 4 | 34.1 |
| pathophysiology | 2026 | 5 | 79.8 |
| physiology | 2026 | 5 | 70.6 |
| biopharmaceutics | 2026 | 4 | 21 |
| biopharmaceutics | 2025 | 4 | 21 |
| biopharmaceutics | 2024 | 4 | 22 |
| medicinal chemistry | 2026 | 5 | 53 |
| medicinal chemistry | 2025 | 4 | 40.2 |
| medicinal chemistry | 2024 | 4 | 46.1 |
| pharmaceutical biotechnology | 2026 | 4 | 11.4 |
| pharmaceutical biotechnology | 2025 | 4 | 20 |
| pharmaceutical biotechnology | 2024 | 4 | 16.5 |
| pharmaceutics | 2026 | 4 | 25.3 |
| pharmaceutics | 2025 | 3 | 22 |
| pharmaceutics | 2024 | 3 | 19.8 |
| pharmacogenomics | 2025 | 4 | 33.8 |
| pharmacogenomics | 2024 | 4 | 36.3 |
| pharmacokinetics | 2026 | 4 | 33.7 |
| pharmacokinetics | 2025 | 4 | 30.9 |
| pharmacokinetics | 2024 | 3 | 20.8 |
| pharmacology | 2026 | 5 | 81.9 |
| pharmacology | 2025 | 5 | 77.8 |
| pharmacology | 2024 | 5 | 71.6 |
| toxicology | 2026 | 5 | 61.4 |
| toxicology | 2025 | 4 | 45.1 |
| toxicology | 2024 | 4 | 46.1 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| pharmaceutics | |
| pharmaceutical biotechnology | |
| biopharmaceutics | |
| biochemistry | |
| molecular and cell biology | |
| anatomy | |
| pharmacokinetics | |
| medicinal chemistry |
| anatomy | 2026 | 4 | 36.9 |
| biochemistry | 2026 | 4 | 24.7 |
| immunology | 2026 | 5 | 67.9 |
| microbiology | 2026 | 5 | 52.9 |
| molecular and cell biology | 2026 | 4 | 34.1 |
| pathophysiology | 2026 | 5 | 79.8 |
| physiology | 2026 | 5 | 70.6 |
| biopharmaceutics | 2026 | 4 | 21 |
| biopharmaceutics | 2025 | 4 | 21 |
| biopharmaceutics | 2024 | 4 | 22 |
| medicinal chemistry | 2026 | 5 | 53 |
| medicinal chemistry | 2025 | 4 | 40.2 |
| medicinal chemistry | 2024 | 4 | 46.1 |
| pharmaceutical biotechnology | 2026 | 4 | 11.4 |
| pharmaceutical biotechnology | 2025 | 4 | 20 |
| pharmaceutical biotechnology | 2024 | 4 | 16.5 |
| pharmaceutics | 2026 | 4 | 25.3 |
| pharmaceutics | 2025 | 3 | 22 |
| pharmaceutics | 2024 | 3 | 19.8 |
| pharmacogenomics | 2025 | 4 | 33.8 |
| pharmacogenomics | 2024 | 4 | 36.3 |
| pharmacokinetics | 2026 | 4 | 33.7 |
| pharmacokinetics | 2025 | 4 | 30.9 |
| pharmacokinetics | 2024 | 3 | 20.8 |
| pharmacology | 2026 | 5 | 81.9 |
| pharmacology | 2025 | 5 | 77.8 |
| pharmacology | 2024 | 5 | 71.6 |
| toxicology | 2026 | 5 | 61.4 |
| toxicology | 2025 | 4 | 45.1 |
| toxicology | 2024 | 4 | 46.1 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
What does PEBC evidence add to the picture of achievement?
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
What becomes clearer when these perspectives are considered together?
Bringing internal program performance, assessment-quality estimates, graduating‑student self-report, and the 2025 PEBC results together makes clearer where different measures align and where they diverge. Internal course averages for 2025–2026 are highest in Year 1, lower in Year 2, and lowest in Year 3, with modest increases from earlier reporting years in each year. Test-quality information is available at the stream level for all years, while test‑level reliability estimates vary: many Year 1 estimates sit in a generally acceptable range, Year 2 is mixed, and some Year 3 estimates are noticeably lower. In the most recent survey graduating students report relatively strong preparedness for the Scholar role. The 2025 PEBC MCQ and OSCE results (single reporting year) show a mixed picture versus national values: some MCQ competencies are slightly weaker than national values while others are slightly stronger; OSCE competencies are stronger in Patient Care and Knowledge but weaker in Product Distribution. Taken together, these perspectives suggest relative strengths in applied and patient‑centred skills on performance and OSCE measures, alongside less consistent performance on some MCQ competency measures.
These sources use different measures, scales, and reporting periods and must be kept separate when interpreting results. Do not pool internal means, test reliabilities, PEBC MCQ and OSCE scores, or self‑report data; differences in test‑level reliability—particularly the lower estimates in Year 3—mean comparisons across years or tests require contextual information about test design and scope. The PEBC data are from 2025 only, so movement over time cannot be assessed, and the graduating‑student AFPC rating is from the most recent survey year only, so stability across earlier years is not known.
Bringing internal program performance, assessment-quality estimates, graduating‑student self-report, and the 2025 PEBC results together makes clearer where different measures align and where they diverge. Internal course averages for 2025–2026 are highest in Year 1, lower in Year 2, and lowest in Year 3, with modest increases from earlier reporting years in each year. Test-quality information is available at the stream level for all years, while test‑level reliability estimates vary: many Year 1 estimates sit in a generally acceptable range, Year 2 is mixed, and some Year 3 estimates are noticeably lower. In the most recent survey graduating students report relatively strong preparedness for the Scholar role. The 2025 PEBC MCQ and OSCE results (single reporting year) show a mixed picture versus national values: some MCQ competencies are slightly weaker than national values while others are slightly stronger; OSCE competencies are stronger in Patient Care and Knowledge but weaker in Product Distribution. Taken together, these perspectives suggest relative strengths in applied and patient‑centred skills on performance and OSCE measures, alongside less consistent performance on some MCQ competency measures.
These sources use different measures, scales, and reporting periods and must be kept separate when interpreting results. Do not pool internal means, test reliabilities, PEBC MCQ and OSCE scores, or self‑report data; differences in test‑level reliability—particularly the lower estimates in Year 3—mean comparisons across years or tests require contextual information about test design and scope. The PEBC data are from 2025 only, so movement over time cannot be assessed, and the graduating‑student AFPC rating is from the most recent survey year only, so stability across earlier years is not known.
Bringing internal program performance, assessment-quality estimates, graduating‑student self-report, and the 2025 PEBC results together makes clearer where different measures align and where they diverge. Internal course averages for 2025–2026 are highest in Year 1, lower in Year 2, and lowest in Year 3, with modest increases from earlier reporting years in each year. Test-quality information is available at the stream level for all years, while test‑level reliability estimates vary: many Year 1 estimates sit in a generally acceptable range, Year 2 is mixed, and some Year 3 estimates are noticeably lower. In the most recent survey graduating students report relatively strong preparedness for the Scholar role. The 2025 PEBC MCQ and OSCE results (single reporting year) show a mixed picture versus national values: some MCQ competencies are slightly weaker than national values while others are slightly stronger; OSCE competencies are stronger in Patient Care and Knowledge but weaker in Product Distribution. Taken together, these perspectives suggest relative strengths in applied and patient‑centred skills on performance and OSCE measures, alongside less consistent performance on some MCQ competency measures.
These sources use different measures, scales, and reporting periods and must be kept separate when interpreting results. Do not pool internal means, test reliabilities, PEBC MCQ and OSCE scores, or self‑report data; differences in test‑level reliability—particularly the lower estimates in Year 3—mean comparisons across years or tests require contextual information about test design and scope. The PEBC data are from 2025 only, so movement over time cannot be assessed, and the graduating‑student AFPC rating is from the most recent survey year only, so stability across earlier years is not known.
What questions does the achievement evidence warrant further consideration?
Where did this information come from, and how was it prepared?
This workspace brings together several different perspectives on achievement for the selected pharmacy stream: performance in program assessments, information about how written exams are functioning, graduating-student self-report, and PEBC licensure results.
These sources answer different questions and are kept separate. Program assessments show performance within the curriculum, graduating-student surveys describe perceived preparedness and development, and PEBC provides an external perspective after the program.
Program-performance figures summarize student exam performance within each course and then across courses in the stream. Program years are shown separately, and the most recent academic year can be compared with earlier academic years using the same calculation.
Assessment-quality figures provide additional context about how individual written exams and exam questions are functioning. Exam reliability and item statistics can help identify results that deserve closer review, but they do not establish whether an exam adequately covers the intended curriculum.
Exam reliability describes an individual assessment, not the reliability of a final course grade that combines several assessments.
AFPC professional-role preparedness and CCAPP knowledge-and-skill development use six-point response scales. The coloured bars show the full distribution of student responses rather than reducing the result to a single score. Hover or keyboard focus provides the median and the share of responses in the two most favourable categories.
The professional-role figure compares the same role across available survey years. The knowledge-and-skill figure shows the eight lowest-rated stream-relevant topics in the most recent survey; the mean is used only to select those topics, while the displayed evidence remains the full response distribution.
These are student self-reports. They complement demonstrated achievement evidence but are not treated as direct measures of competence.
PEBC results are displayed on their original assessment-specific scales. MCQ competency results, OSCE competency results, and the available 1–4 OSCE global ratings are shown separately. Within each figure, the most recent reporting year appears first so changes can be followed over time.
UAlberta results are shown alongside the national value when that comparison already exists in the governed PEBC evidence. Missing national values are left absent rather than reconstructed.
PEBC reporting years are not treated as equivalent to the academic-cycle selector, and relationships to a stream establish relevance rather than showing that the stream caused the result.
The report first prepares the quantitative evidence and its source-specific limits. AI-assisted writing is then used to create concise educator-facing What stands out notes, cross-evidence orientation, and review questions from those prepared records.
AI-assisted writing does not calculate the figures, combine unlike scales, decide whether learning outcomes have been achieved, determine why a pattern occurred, or recommend curriculum changes. Those judgments remain with the educators reviewing the evidence.
The written summaries are prepared before the report is displayed. Opening or browsing this report does not send a new request to an AI service.
A visible difference between academic years, survey years, or PEBC reporting years does not by itself establish an educationally important improvement or decline. Each source should first be interpreted on its own scale and within its own reporting period.
When evidence is missing, not comparable, unavailable for a stream, or reported on a different scale, the workspace keeps that limitation visible rather than filling the gap or creating a combined achievement score.